NEW YORK & AACHEN, Germany--(BUSINESS WIRE)--Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the ...

The European Investment Bank (EIB) is providing €20 million in venture-debt financing to German medical-technology company Protembis to develop a next-generation device for protecting the brains of ...

Only CEP Trial Designed as a Superiority Trial using DW-MRI to Demonstrate Effectiveness Against the Currently Approved Sentinel Device NEW YORK & AACHEN, Germany–(BUSINESS WIRE)–April 2, 2024– ...

Protembis GmbH received €20 million (US$21.66 million) in financing from the European Investment Bank to develop its cerebral embolic protection system, Protembo. The intra-aortic filter device ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

AACHEN, Germany--(BUSINESS WIRE)--The Managing Directors and founders of Protembis GmbH, Karl von Mangoldt and Conrad Rasmus, have successfully closed a Series A financing round in a structured ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

NEW YORK, NY—Yet again, use of the Sentinel cerebral protection system (Boston Scientific) has not been shown to significantly improve clinical outcomes for patients undergoing TAVI, according to the ...

US hospitals pulled back on their use of cerebral embolic protection during TAVI after publication of the PROTECTED TAVR results, a new analysis affirms. The proportion of procedures done with the ...